{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:18:24Z","timestamp":1789676304090,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.2515\/therapie\/2012014","type":"journal-article","created":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T08:27:07Z","timestamp":1343809627000},"page":"157-160","source":"Crossref","is-referenced-by-count":6,"title":["Suivi th\u00e9rapeutique pharmacologique du stiripentol"],"prefix":"10.1016","volume":"67","author":[{"given":"Marie-Cl\u00e9mence","family":"Verdier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tribut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00e8le","family":"Bentu\u00e9-Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.2515\/therapie\/2012014_bb0760","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1528-1157.1984.tb03448.x","article-title":"Michaelis-Menten kinetics of stiripentol in normal humans","volume":"25","author":"Levy","year":"1984","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2012014_bb0765","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.braindev.2009.01.001","article-title":"Dravet syndrome or genetic (generalized) epilepsy with febrile seizures plus?","volume":"31","author":"Scheffer","year":"2009","journal-title":"Brain Dev"},{"key":"10.2515\/therapie\/2012014_bb0770","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neuropharm.2008.06.004","article-title":"The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator","volume":"56","author":"Fisher","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.2515\/therapie\/2012014_bb0775","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1517\/13543784.14.7.905","article-title":"Stiripentol","volume":"14","author":"Chiron","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"10.2515\/therapie\/2012014_bb0780","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.nurt.2006.10.001","article-title":"Stiripentol","volume":"4","author":"Chiron","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.2515\/therapie\/2012014_bb0785","first-page":"153","article-title":"Stiripentol","volume":"3","author":"Vincent","year":"1991","journal-title":"Epilepsy Res Suppl"},{"key":"10.2515\/therapie\/2012014_bb0790","first-page":"154","article-title":"Stiripentol. A novel antiepileptic drug","volume":"57","author":"Trojnar","year":"2005","journal-title":"Pharmacol Rep"},{"key":"10.2515\/therapie\/2012014_bb0795","series-title":"The treatment of epilepsy","first-page":"657","article-title":"Stiripentol","author":"Eriksson","year":"2009"},{"key":"10.2515\/therapie\/2012014_bb0800","unstructured":"http:\/\/www.theriaque.org."},{"key":"10.2515\/therapie\/2012014_bb0805","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/j.1552-4604.1983.tb01799.x","article-title":"Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity","volume":"23","author":"Levy","year":"1983","journal-title":"J Clin Pharmacol"},{"key":"10.2515\/therapie\/2012014_bb0810","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/clpt.1984.237","article-title":"Stiripentol kinetics in epilepsy: nonlinearity and interactions","volume":"36","author":"Levy","year":"1984","journal-title":"Clin Pharmacol Ther"},{"key":"10.2515\/therapie\/2012014_bb0815","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S0090-9556(25)08990-1","article-title":"The metabolic fate of stiripentol in man","volume":"14","author":"Moreland","year":"1986","journal-title":"Drug Metab Dispos"},{"key":"10.2515\/therapie\/2012014_bb0820","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0920-1211(92)90088-B","article-title":"Comparative anticonvulsant potency and pharmacokinetics of (+)-and (\u2212)-enantiomers of stiripentol","volume":"12","author":"Shen","year":"1992","journal-title":"Epilepsy Res"},{"key":"10.2515\/therapie\/2012014_bb0825","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0163-7258(95)00021-6","article-title":"Clinical pharmacokinetics of new antiepileptic drugs","volume":"67","author":"Walker","year":"1995","journal-title":"Pharmacol Ther"},{"key":"10.2515\/therapie\/2012014_bb0830","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00003495-199448020-00003","article-title":"New anticonvulsant drugs. Focus on flunarizine, fosphenytoin, midazolam and stiripentol","volume":"48","author":"Bebin","year":"1994","journal-title":"Drugs"},{"key":"10.2515\/therapie\/2012014_bb0835","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1528-1157.1993.tb02416.x","article-title":"Stiripentol in atypical absence seizures in children: an open trial","volume":"34","author":"Farwell","year":"1993","journal-title":"Epilepsia"},{"issue":"9242","key":"10.2515\/therapie\/2012014_bb0840","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group","volume":"356","author":"Chiron","year":"2000","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2012014_bb0845","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1177\/08830738060210062101","article-title":"Stiripentol in childhood partial epilepsy: randomized placebo-controlled trial with enrichment and withdrawal design","volume":"21","author":"Chiron","year":"2006","journal-title":"J Child Neurol"},{"key":"10.2515\/therapie\/2012014_bb0850","series-title":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit stiripentol","year":"2011"},{"issue":"Suppl. 7","key":"10.2515\/therapie\/2012014_bb0855","first-page":"112","article-title":"Stiripentol potentiates clobazam in childhood epilepsy: a pharmacological study","volume":"40","author":"Rey","year":"1999","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2012014_bb0860","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1528-1157.1991.tb05254.x","article-title":"Carbamazepine dose requirements during stiripentol therapy: influence of cytochrome P-450 inhibition by stiripentol","volume":"32","author":"Kerr","year":"1991","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2012014_bb0865","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s002280050147","article-title":"Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children","volume":"50","author":"Tran","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"10.2515\/therapie\/2012014_bb0870","first-page":"165","article-title":"Neurophysiological and therapeutic evaluation of stiripentol in epilepsy. Preliminary results","volume":"144","author":"Loiseau","year":"1988","journal-title":"Rev Neurol (Paris)"},{"key":"10.2515\/therapie\/2012014_bb0875","first-page":"605","article-title":"Effects of stiripentol on valproate plasma level and metabolism","volume":"28","author":"Levy","year":"1987","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2012014_bb0880","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1046\/j.0306-5251.2003.01919.x","article-title":"Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human","volume":"56","author":"Cazali","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl. 4","key":"10.2515\/therapie\/2012014_bb0885","first-page":"106","article-title":"Simultaneous analysis of 11 newer antiepileptique drugs by rapid resolution LC triple quadrupole mass spectrometry","volume":"50","author":"Dietmann","year":"2009","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2012014_bb0890","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1528-1157.1983.tb04632.x","article-title":"Pharmacokinetic profile of a new anticonvulsant, stiripentol, in the rhesus monkey","volume":"24","author":"Lin","year":"1983","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2012014_bb0895","first-page":"21","article-title":"M\u00e9thodologie pour l\u2019\u00e9valuation du niveau de preuve du suivi th\u00e9rapeutique pharmacologique","volume":"23","author":"Le Guellec","year":"2009","journal-title":"La Lettre du Pharmacologue"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059571630823X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059571630823X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T07:34:05Z","timestamp":1743924845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004059571630823X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S004059571630823X"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2012014","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}